Who are Contineum Therapeutics, Inc.'s main suppliers?

Contineum Therapeutics, Inc. (CTNM) key suppliers include: GOLDMAN-SACHS-CO-LLC, LEERINK-PARTNERS-LLC. View the full supplier network at chainsifter.com/chain/CTNM.

Who are Contineum Therapeutics, Inc.'s major customers?

Contineum Therapeutics, Inc. (CTNM) key customers include: J-J, JJDC, AstraZeneca PLC, AstraZeneca PLC, Structure Therapeutics Inc. and 10 more. View the full customer network at chainsifter.com/chain/CTNM.

What sector is Contineum Therapeutics, Inc. in?

Contineum Therapeutics, Inc. (CTNM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Contineum Therapeutics, Inc. (CTNM) Supply Chain: 20 Verified Relationships

2Suppliers

15Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Contineum Therapeutics, Inc. (CTNM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

4Distinct source URLs

8High confidence

0.785Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Contineum Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GOLDMAN-SACHS-CO-LLC	GOLDMAN-SACHS-CO-LLC	90%	The Underwriters purchased the Shares from the Company pursuant to the Underwriting Agreement
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	90%	On May 14, 2025, the Company entered into a Sales Agreement with Leerink Partners LLC, pursuant to which the Company may from time to time issue and sell through Leerink Partners, acting as the Compa…

Contineum Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
J-J	J-J	92%	Pursuant to the terms of the J&J License Agreement, the Company granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications.
JJDC	JJDC	90%	Separately, we received a $25.0 million equity investment from JJDC.
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and…
AZN	AstraZeneca PLC	72%	om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can result in substantial criminal fines and …
GPCR	Structure Therapeutics Inc.	72%	om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can result in substantial criminal fines and …
GPCR	Structure Therapeutics Inc.	72%	Reciprocal relationship from GPCR graph: Reciprocal relationship from CTNM graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from CTNM graph: om, or engaging in the sale or supp…
GSK	GSK plc	72%	om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can result in substantial criminal fines and …
GSK	GSK plc	72%	Reciprocal relationship from GSK graph: Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and…
LLY	Eli Lilly and Company	72%	om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can result in substantial criminal fines and …
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons a…
NVSEF	Novartis AG	72%	om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can result in substantial criminal fines and …
UTHR	United Therapeutics Corporation	72%	Reciprocal relationship from UTHR graph: Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons an…
UTHR	United Therapeutics Corporation	72%	om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can result in substantial criminal fines and …
EMERGING-GROWTH-COMPANY	EMERGING-GROWTH-COMPANY	62%	hts). Options are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless we determine the option provides a material right w…

Contineum Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CTNM-DEBT-8910	Warrants outstanding: 0	90%	xbrl warrant detail from xbrl 2025-12-31.
CTNM-DEBT	Debt stack $7.0M	90%	Market cache reports total debt of $7.0M.
CTNM-DEBT-8911	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Contineum Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Contineum Therapeutics, Inc..

Contineum Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CTNM-OWNER-JOHNSON-JOHNSON	JOHNSON & JOHNSON	90%	13F overlay lists JOHNSON & JOHNSON as top holder; 91 tracked holders.

Contineum Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ALLO	Allogene Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
SLGL	Sol-Gel Technologies Ltd.	100.00	2

Contineum Therapeutics, Inc. Supply Chain